KRAS and cancer: We found that hotspot KRAS+/TP53+ mutations occurred in approximately 8% of cancer patients referred to our institution for phase I clinical trials, and that the KRAS G13 mutation, as well as the TP53 R273 mutation, were associated with poor OS.